Therapentic Advances In Multiple Sclerosis

Abstract

Severak evidences suggest that immunopathological factors are critically involved in the pathogenesis of multiple sclerosis. Although significant progress has recently been obtained in the thraphy of multiple sclerosis, none of these therapies are entirely satisfactory. The three clinical trials demonstrated that IFN-ß Reference source not found. reduced the frequency and severity of exacerbations, slowed the accumulation of disability and supressed MRI activity and lesion accrual. Phase III multicentre copolimer-1 trial showed that glatiramer acetate had positive therapeutic effects in reducing relapse rate in relapsing-remitting multiple sclerosis (RRMS). Intravenous immunoglobulin was also shown to be beneficial in the treatment of RRMS.